Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years
Cangene Corporation reported that its contract with the U.S. Centers for Disease Control and Prevention for the supply of Vaccinia Immune Globulin Intravenous (Human) ("VIG") has been extended for five more years. The original five-year contract was signed in August 2002, and under that contract Cangene developed and delivered VIG product to the U.S. Strategic National Stockpile ("SNS"). Although a supply of product is already maintained within the SNS, the extended contract supports licensing requirements, ongoing stability studies, further clinical testing and development projects, and could provide for future orders.
VIG is a hyperimmune product to be used in treating and preventing certain types of severe complications that may be associated with smallpox vaccination, and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified, specialty antibodies made from plasma.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Diabetes_mellitus
RETSCH relocates to new, larger premises
Genetic testing for personalized nutrition leads to better outcomes

Seeing more with PET scans - New chemistry for medical imaging

Bioactive film improves how implants bond with bone in animal study
Refractory_period
Promega and Leica Microsystems Sign Agreement to Develop Fluorescent Ligands Enabling Live Cell Imaging at the Sub 100 nm Range

Little Trust in Dr. ChatGPT - There is still a long way to go before people trust medical advice from an AI
UCLA scientists make paralyzed rats walk again after spinal-cord injury
